Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer. | UCSF Helen Diller Family Comprehensive Cancer Center

Author List

Jacqueline V. Aredo, Anatoly Urisman, Matthew A. Gubens, Claire Mulvey, Greg M. Allen, Julia K. Rotow, Daniel Lucas Kerr, Turja Chakrabarti, Bianca Bacaltos, Megan Gee, Kirk Jones, Dara L. Aisner, Tejas Patil, Erin Lynn Schenk, Trever G. Bivona, Jonathan W. Riess, Melissa Coleman, Johannes Ruediger Kratz, David Jablons, Collin M. Blakely

Publication

Journal of Clinical Oncology

Publication ID (Profile URL)

https://researcherprofiles.org/profile/420600753

Publication Year

2023

Publication Title

Jacqueline V. Aredo, Anatoly Urisman, Matthew A. Gubens, Claire Mulvey, Greg M. Allen, Julia K. Rotow, Daniel Lucas Kerr, Turja Chakrabarti, Bianca Bacaltos, Megan Gee, Kirk Jones, Dara L. Aisner, Tejas Patil, Erin Lynn Schenk, Trever G. Bivona, Jonathan W. Riess, Melissa Coleman, Johannes Ruediger Kratz, David Jablons, Collin M. Blakely. Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):8508-8508.